Intense competition between innovative companies and generic companies has recently increased significantly in the pharmaceutical field in Japan. Once a patent covering a drug belonging to an innovative company has expired, generic companies can start to market the patented drug at a lower price. One powerful countermeasure that innovative companies can use against generic competitors is the patent term extension (PTE) system. It is vital that both types of pharmaceutical companies fully understand the patent term extension system to maximise their profits.
Japan's Patent Law says that the PTE system can be applied to a patent directed to pharmaceuticals or agricultural chemicals. It is possible to extend the patent term by up to five years. However, a PTE is applicable only if the patentee or registered licensee was not able to perform the patented invention because of a delay by the Japanese regulatory authorities in granting marketing approval for the pharmaceutical or agricultural chemical corresponding to the patented invention. To obtain a PTE it is necessary to submit a PTE application to the Japanese Patent Office (JPO). The JPO's examination guidelines include standards for examining PTE applications.
In 2009, the Intellectual Property High Court (IP High Court) issued several decisions regarding how PTE applications should be examined. These decisions suggest new standards for examining PTE applications, which differ from those used by the JPO in the past. These decisions will have great impact on the PTE system in Japan.
Pharmaceutical formulations
Article 68bis of Japan's Patent Law states that "the uses of the patent right of which the term has been extended ... shall not extend to acts other than the working of the patented invention with respect to the product (where ... if any specific use of such product to be used was specified, the product for such specific use) ...". Therefore, the scope of an extended Japanese patent is limited to a specific use of a specific product.
The JPO's examination guidelines explain that a PTE application should be filed based on a market approval of a specific use of a specific product. Regarding the meaning of the term "a specific use of a specific product" for pharmaceuticals, the guidelines mention that a specific product means an "active pharmaceutical ingredient (API)" and a specific use means a "use of the API". In addition, if both the API and its use are not new, the PTE application will be rejected, in accordance with the guidelines.
Several court decisions in the past also dictated that a PTE application must be filed based on a marketing approval of a drug whose "API" or "use of the API" is new.
One example of such a decision is Tokyo High Court Decision H10 (Gyo-Ke) No. 364 issued on February 10 2000. In this case, a marketing approval was issued for the use of ondansetron in children for ameliorating digestive system symptoms such as vomiting due to an anti-cancer agent (1996). The patentee filed a PTE application based on this approval. The JPO rejected the application based on the following prior marketing approval for the same API and its use: use of ondansetron in adults for ameliorating digestive system symptoms such as vomiting due to an anti-cancer agent (1994). The patentee appealed to the Tokyo High Court in 1998, arguing that it was not able to market the product for children until 1996, and therefore the PTE should be allowed. However, the Tokyo High Court upheld the JPO's decision. Specifically, the Tokyo High Court stated that the PTE based on the marketing approval in 1996 should not be allowed because the patentee was able to market its product including ondansetron for ameliorating digestive system symptoms such as vomiting due to an anti-cancer agent for adults before 1996, and therefore there was not, before 1996, a period of time in which working of the patented invention, in terms of the API and the use of the API, was not possible.
Another example is Tokyo High Court Decision H7 (Gyo-Ke) No. 155 issued on March 5 1998. In this case, the patentee filed a PTE application based on the following marketing approval: use of ketotifen fumarate for treating allergic rhinitis (as a nasal drop). This application was rejected based on the following prior marketing approval: use of ketotifen fumarate for treating allergic rhinitis (as a capsule).
The current standards make it difficult to obtain a PTE for a new pharmaceutical formulation, if both the API in the new formulation and the use of the API are not new.
IP High Court decisions in 2009
Recent decisions of the Court (IP High Court H20 (Gyo-ke) Nos. 10458 to 10460), which were issued on May 29 2009, deviate from the standards of the JPO's guidelines. In one of these cases, a marketing approval was issued for the use of morphine hydrochloride for analgesia in various cancers associated with medium to heavy pain (as a 30mg capsule). The patentee filed a PTE application claiming a capsule comprising morphine hydrochloride based on this approval. The JPO rejected the application based on the following prior marketing approval for the same API and its use: use of morphine hydrochloride for analgesia in various cancers associated with medium to heavy pain (as 5mg and 10mg oral liquids). Although this rejection followed the JPO's guidelines and was consistent with the prior court decisions, the IP High Court reversed the JPO's decision. The judges of IP High Court commented that regardless of whether the new drug has the same API and its use as those of the prior-approved drug, the PTE should be approved if the patentee was not able to perform the patented invention until the marketing approval of the new drug was issued and marketing of the new approved drug is included in the scope of the patent. In this case, the new approved 30mg capsule of morphine hydrochloride is included in the scope of the patent claiming a capsule of morphine hydrochloride, while the prior-approved 5mg and 10mg oral liquids of morphine hydrochloride are not. The patentee was not able to perform the patented invention until the marketing approval of the capsule was issued.
According to the JPO's current examination guidelines and prior court decisions, if a drug has the same API and the same use as those of a prior-approved drug, even though the quantity or structure of the drug is different from that of the earlier one, the PTE application should be rejected.
However, based on these recent decisions, in the future PTE applications for patents regarding new pharmaceutical formulations will likely be approved based on marketing approvals of drugs with a new quantity or structure, such as a new dosage form. Although it is difficult to receive a grant for PTE applications based on a marketing approval of a new drug delivery system (DDS) formulation under the present JPO guidelines, the future PTE system in Japan may allow for extensions on such a marketing approval.
Period for extension
Article 67(2) of the Japanese Patent Law explains that the period for extension of a patent is equal to the period of time when the working of a patented invention was not possible until a marketing approval was issued. Specifically, the JPO's examination guidelines say that in the case of pharmaceuticals, the period of time is the shorter of the following two periods: (1) from the registration of a patent to the time that marketing approval was granted by the Japanese regulatory authority, and (2) from the start of clinical trials to the time that marketing approval was granted by the Japanese regulatory authority.
Regarding places where clinical trials are carried out, the JPO has clarified that clinical trials may be performed in Japan and other foreign countries. For example, if clinical trials are performed abroad and later in Japan without interruption, the extended period may be from the start of the trials in the foreign country to the time that marketing approval was issued in Japan. In this case, all the trials carried out abroad and in Japan must be essential to the granting of marketing approval in Japan.
The decisions of the IP High Court in H20 (Gyo-ke) Nos. 10486 and 10487, which were issued on October 28 2009, clearly state that clinical trials performed in a foreign country must be essential to the marketing approval in Japan to ensure that the period of the clinical trials is included in the period for extension. In these cases, as a part of clinical trials to obtain marketing approval in Japan, the patentee carried out clinical trials in the US regarding the use of levofloxacin against legionella infectious diseases. Marketing approval for the use of levofloxacin was then issued in Japan and the patentee filed PTE applications based on the marketing approval. The PTEs were allowed. However, a number of generic companies requested the invalidation of the PTEs at the JPO. The generic companies argued that the clinical trials carried out in the US were not essential to obtaining marketing approval in Japan, and thus the period of the clinical trials in the US should not be included in the period for extension of the patents.
In response, the patentee argued that the clinical trials carried out in the US were necessary for obtaining marketing approval in Japan, submitting several pieces of evidence to that effect. However, the JPO upheld the generic companies' arguments. Although the patentee then appealed to the IP High Court, this appeal was not successful. The judges commented that the period of the clinical trials performed in the US should not be included in the period for extension, because it was not able to be accepted that the clinical trials were necessary for the marketing approval in Japan.
According to these decisions, although clinical trials can be carried out in foreign countries for the purposes of obtaining marketing approval in Japan (and the period of the clinical trials may be included in the period for extension of a patent), it should be noted that the clinical trials must be essential to obtaining marketing approval. In other words, unless the patentee has strong arguments and enough evidence to persuade judges to accept that clinical trials carried out in foreign countries are essential to a marketing approval in Japan, there is a risk that the period of time in which clinical trials were performed in foreign countries will be excluded from the period for the extension of a patent.
Revised examination standards required
The recent decisions of the IP High Court described above have raised new issues for examining PTE applications. These issues may have been raised due to a lack of clarity or unreasonableness of the standards as set out in the JPO's examination guidelines.
However, the JPO's examination standards have not yet been revised in accordance with the IP High Court decisions. Accordingly, revisions of the JPO's guidelines are necessary so that the standards for examining PTE applications will become clear and reasonable for everyone.
For example, at the moment PTEs are not granted based on marketing approvals for new formulations such as a DDS preparation whose API and its use are not new. However, since a DDS preparation is an important technology, it would be preferable that the standards of the JPO are revised to allow PTEs for such important technologies to encourage their development.
In addition, the examination guidelines do not specifically define how clinical trials performed overseas are handled in the course of examinations of PTE applications. Accordingly, it would also be desirable to revise the guidelines so as to include specific standards and some example cases for examining PTE applications based on a marketing approval for which clinical trials were carried out in foreign countries.
Shintaro Yamada |
|
Shintaro Yamada is a patent attorney with Shiga International Patent Office. He specialises in biochemistry and has a masters degree from the department of chemistry at Tokyo Metropolitan University. Shintaro Yamada advises companies in a range of fields including cosmetics, polymers, foods, pharmaceuticals and biotechnology. He has particular experience in the analysis of intracellular proteins, especially intracellular phosphorylated proteins and protein interaction accompanying this condition. |